Diurnal (DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building a long-term ‘Adrenal Franchise’. Its first drug, Alkindi, is being rolled out through key European markets, and sales exceeded £1.1m in 1H’20. Despite unexpected Phase III trial results, positive feedback from the EMA has opened a pathway for regulatory submission of Chronocort for adult CAH and AI in Europe. Discussions with potential US partners for both products are also expected to crystallise in the first half of calendar 2020.
If you'd like to be introduced to the team at Diurnal Group Plc, get in touch.Request a meeting